JP2021052791A5 - - Google Patents

Download PDF

Info

Publication number
JP2021052791A5
JP2021052791A5 JP2020211507A JP2020211507A JP2021052791A5 JP 2021052791 A5 JP2021052791 A5 JP 2021052791A5 JP 2020211507 A JP2020211507 A JP 2020211507A JP 2020211507 A JP2020211507 A JP 2020211507A JP 2021052791 A5 JP2021052791 A5 JP 2021052791A5
Authority
JP
Japan
Prior art keywords
drug
nucleic acid
conjugate according
linker
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020211507A
Other languages
English (en)
Japanese (ja)
Other versions
JP7138965B2 (ja
JP2021052791A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021052791A publication Critical patent/JP2021052791A/ja
Publication of JP2021052791A5 publication Critical patent/JP2021052791A5/ja
Priority to JP2022137571A priority Critical patent/JP7536328B2/ja
Application granted granted Critical
Publication of JP7138965B2 publication Critical patent/JP7138965B2/ja
Priority to JP2024124515A priority patent/JP2024153831A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020211507A 2016-06-20 2020-12-21 抗体－薬物コンジュゲート Active JP7138965B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022137571A JP7536328B2 (ja) 2016-06-20 2022-08-31 抗体－薬物コンジュゲート
JP2024124515A JP2024153831A (ja) 2016-06-20 2024-07-31 抗体－薬物コンジュゲート

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016122187 2016-06-20
JP2016122187 2016-06-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018524078A Division JP6823269B2 (ja) 2016-06-20 2017-06-19 抗体−薬物コンジュゲート

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022137571A Division JP7536328B2 (ja) 2016-06-20 2022-08-31 抗体－薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021052791A JP2021052791A (ja) 2021-04-08
JP2021052791A5 true JP2021052791A5 (https=) 2021-07-26
JP7138965B2 JP7138965B2 (ja) 2022-09-20

Family

ID=60784523

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018524078A Active JP6823269B2 (ja) 2016-06-20 2017-06-19 抗体−薬物コンジュゲート
JP2020211507A Active JP7138965B2 (ja) 2016-06-20 2020-12-21 抗体－薬物コンジュゲート
JP2022137571A Active JP7536328B2 (ja) 2016-06-20 2022-08-31 抗体－薬物コンジュゲート
JP2024124515A Pending JP2024153831A (ja) 2016-06-20 2024-07-31 抗体－薬物コンジュゲート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018524078A Active JP6823269B2 (ja) 2016-06-20 2017-06-19 抗体−薬物コンジュゲート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022137571A Active JP7536328B2 (ja) 2016-06-20 2022-08-31 抗体－薬物コンジュゲート
JP2024124515A Pending JP2024153831A (ja) 2016-06-20 2024-07-31 抗体－薬物コンジュゲート

Country Status (6)

Country Link
US (2) US20190240346A1 (https=)
EP (2) EP4212176A1 (https=)
JP (4) JP6823269B2 (https=)
CN (1) CN109310765A (https=)
DK (1) DK3473270T5 (https=)
WO (1) WO2017221883A1 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
DK3473270T5 (da) * 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3691657A4 (en) 2017-10-04 2021-07-21 Avidity Biosciences, Inc. NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
WO2020028836A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
WO2020028842A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
EP3829645A4 (en) * 2018-08-02 2022-05-18 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS
EP3830130A4 (en) * 2018-08-02 2022-05-18 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating centronuclear myopathy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL280536B2 (en) * 2018-08-02 2024-12-01 Dyne Therapeutics Inc Complexes targeting transferrin receptor and uses thereof
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2019314538B2 (en) * 2018-08-02 2025-03-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) * 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20210086601A (ko) * 2018-08-02 2021-07-08 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
US20210317226A1 (en) * 2018-08-02 2021-10-14 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating pompe disease
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
CN114375296A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
CN119874910A (zh) * 2019-06-07 2025-04-25 达因疗法公司 制备蛋白质-寡核苷酸复合物的方法
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
KR20220125801A (ko) * 2020-01-10 2022-09-14 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
CA3163283A1 (en) * 2020-01-10 2021-07-15 Romesh R. Subramanian Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
AU2021206234A1 (en) * 2020-01-10 2022-09-01 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20230103793A1 (en) * 2020-01-31 2023-04-06 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
CN115427059A (zh) * 2020-01-31 2022-12-02 达因疗法公司 抗转铁蛋白受体（tfr）抗体及其用途
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
SI4126066T1 (sl) 2020-03-27 2026-04-30 Avidity Biosciences, Inc. Sestavki in postopki zdravljenja mišične distrofije
KR20230046297A (ko) * 2020-07-23 2023-04-05 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
EP4271478A4 (en) * 2020-12-31 2025-03-26 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR TREATING FACIOSCAPULOHUMERAL MYOPATHY
WO2022202688A1 (ja) 2021-03-26 2022-09-29 株式会社フジミインコーポレーテッド 研磨方法および半導体基板の製造方法、ならびに研磨用組成物セット
EP4323008A4 (en) * 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
WO2023027125A1 (ja) 2021-08-24 2023-03-02 ペプチドリーム株式会社 ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート
WO2023034409A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
WO2023034870A2 (en) 2021-09-01 2023-03-09 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing dmpk expression
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
WO2024187057A2 (en) 2023-03-08 2024-09-12 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
AU2024308906A1 (en) * 2023-06-30 2026-02-05 Atrium Therapeutics, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
TW202517685A (zh) 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025168041A1 (zh) * 2024-02-08 2025-08-14 成都新泽利医药科技有限公司 治疗2型炎症性疾病的组合物和方法
WO2025207959A1 (en) 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
CN118897089B (zh) * 2024-08-09 2026-02-17 山西医科大学 Sarcolipin在早期无创诊断I型射血分数保留性心衰中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8903021D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
DE69233046T2 (de) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU767394C (en) * 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト，インコーポレイテッド トランスフェリンレセプター抗体
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
CN101687927B (zh) * 2007-05-15 2013-10-30 霍夫曼-拉罗奇有限公司 针对g蛋白偶联的受体（gpcr）的抗体
CA2796722C (en) * 2010-04-19 2021-06-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2016007741A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
TWI812873B (zh) * 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
JP2019513371A (ja) * 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
DK3473270T5 (da) * 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel

Similar Documents

Publication Publication Date Title
JP2021052791A5 (https=)
JP2023103244A5 (https=)
Chi et al. Safety of antisense oligonucleotide and siRNA-based therapeutics
Zuckerman et al. Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Alterman et al. Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain
Höbel et al. Polyethylenimine/small interfering RNA‐mediated knockdown of vascular endothelial growth factor in vivo exerts anti‐tumor effects synergistically with Bevacizumab
Judge et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Kang et al. Evaluation of folate‐PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo
Hayashi et al. Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy
AU2013296321B2 (en) Modified RNAi agents
US11085044B2 (en) miRNA for treatment of breast cancer
JP2016506240A5 (https=)
JP7023834B2 (ja) 治療用オリゴヌクレオチド
CN116887842A (zh) 用于抑制angptl3的新型rna组合物和方法
CN115176011A (zh) 用于抑制pcsk9的组合物和方法
US20160168573A1 (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
CN120591279A (zh) 用于治疗癌症的方法和组合物
KR20220110723A (ko) 암 치료를 위한 TGF-β SIRNA 및 PDL1 SIRNA의 공동 전달
AU2021413862A9 (en) Template directed immunomodulation for cancer therapy
CA2530125A1 (en) Use of double-stranded ribonucleic acid for inducing cell lysis
Yang et al. Targeted TFO delivery to hepatic stellate cells
JP7728531B2 (ja) Ｅｐｈ２ａアプタマーおよびその使用
US11149274B2 (en) Methods and compositions for managing vascular conditions
Keyvani et al. Insight into RNA-based therapies for ovarian cancer
US20130123336A1 (en) Polyplexes of Hydrophobically-Modified siRNA for Delivery of siRNA